IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.112
EU - Europa 5.259
AS - Asia 4.806
SA - Sud America 658
AF - Africa 50
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 17.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.001
SG - Singapore 2.043
CN - Cina 1.465
UA - Ucraina 968
IE - Irlanda 849
GB - Regno Unito 743
SE - Svezia 638
TR - Turchia 600
FR - Francia 588
BR - Brasile 567
IT - Italia 514
DE - Germania 357
IN - India 248
FI - Finlandia 218
VN - Vietnam 202
RU - Federazione Russa 169
CA - Canada 62
PL - Polonia 49
BE - Belgio 44
HK - Hong Kong 38
AR - Argentina 33
MX - Messico 33
JP - Giappone 32
KR - Corea 32
IQ - Iraq 28
BD - Bangladesh 25
CZ - Repubblica Ceca 22
ZA - Sudafrica 22
ES - Italia 21
NL - Olanda 20
AT - Austria 18
UZ - Uzbekistan 14
EC - Ecuador 13
LT - Lituania 13
VE - Venezuela 13
IR - Iran 12
EU - Europa 11
ID - Indonesia 10
IL - Israele 10
AE - Emirati Arabi Uniti 8
UY - Uruguay 8
CO - Colombia 7
AL - Albania 6
CH - Svizzera 6
EG - Egitto 6
PK - Pakistan 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
KE - Kenya 5
PE - Perù 5
PY - Paraguay 5
CL - Cile 4
DO - Repubblica Dominicana 4
GR - Grecia 4
MA - Marocco 4
NP - Nepal 4
TN - Tunisia 4
AU - Australia 3
JO - Giordania 3
PT - Portogallo 3
RO - Romania 3
RS - Serbia 3
SN - Senegal 3
TW - Taiwan 3
BO - Bolivia 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
NI - Nicaragua 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CR - Costa Rica 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 17.902
Salva come PNG Salva come JPEG
Città #
Singapore 1.513
Jacksonville 1.062
Chandler 1.053
Dublin 843
Southend 558
Dallas 400
Princeton 385
Beijing 339
Izmir 329
Ashburn 323
Nanjing 307
Los Angeles 220
Santa Clara 210
The Dalles 189
Cambridge 177
Wilmington 177
Tongling 140
Boardman 134
Ann Arbor 127
New York 112
Buffalo 111
Nanchang 111
Dearborn 105
Altamura 91
Chieti 63
Munich 62
Woodbridge 62
Ho Chi Minh City 59
São Paulo 58
Hebei 53
Shenyang 50
Tianjin 46
Brussels 43
Council Bluffs 43
Pescara 43
Kunming 42
Redondo Beach 37
Hong Kong 36
Houston 35
Hanoi 34
Brooklyn 33
Stockholm 31
Seoul 30
Jiaxing 29
Boston 28
Tokyo 28
Warsaw 28
Denver 26
London 26
Norwalk 26
Dong Ket 24
Poplar 24
Chicago 23
Hangzhou 23
Hefei 23
Montreal 23
Nuremberg 23
Atlanta 22
Changsha 22
Chennai 22
Orem 22
Helsinki 20
Falls Church 19
Kocaeli 19
Grevenbroich 18
Turku 18
Brno 17
Johannesburg 17
Montesilvano 17
Collecorvino 16
Manchester 16
Washington 16
Phoenix 15
Rome 15
San Mateo 15
Jinan 14
Kraków 14
Lanzhou 14
Moscow 14
Orange 14
Rio de Janeiro 14
San Francisco 14
Tashkent 14
Augusta 13
Hyderabad 13
Leawood 13
Belo Horizonte 12
Ankara 11
Auburn Hills 11
Baghdad 11
Campinas 11
Milan 11
Guangzhou 10
Lappeenranta 10
Salvador 10
Seattle 10
Toronto 10
Changchun 9
Da Nang 9
Düsseldorf 9
Totale 10.851
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 178
90K (Mac-2 BP) in human milk 162
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 159
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 151
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 151
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 148
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 148
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 145
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 141
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 141
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 140
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 137
Prognostic relevance of LGALS3BP in human colorectal carcinoma 135
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 134
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 134
New Targets for Therapy in Pancreatic Cancer 134
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 134
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 133
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 130
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 130
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 128
ERBB3 BINDING ANTIBODY 128
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 127
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 127
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 125
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 124
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 124
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 124
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 123
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 122
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 122
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 121
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 121
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 119
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 118
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 117
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 116
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 114
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 113
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 113
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 113
Surgical treatment of adrenal metastases from non small cell lung cancer 112
DNA ploidy and S-phase fraction in pulmonary carcinoids. 112
Novel inhibitors of pvhl-elongin c binding 112
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 112
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 111
Tyrosine kinase inhibitors 110
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 109
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 109
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 108
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 107
Prognostic value of 90K protein in HIV infection 106
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 106
A Stochastic Model for the HIV/AIDS Dynamic Evolution 106
Prognostic value of a novel circulating serum 90K antigen in breast cancer 104
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 104
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 104
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 104
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 103
Role of 90K protein in asthma and TH2-type cytokine expression. 103
Tumor-derived microvesicles: The metastasomes. 102
Unknown primary tumors 101
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 100
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 100
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 100
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 99
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 99
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 99
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 99
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 98
[Hairy cell leukemia: prognosis and treatment] 98
Increased levels of soluble P-selectin in hypercholesterolemic patients 98
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 98
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 96
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 95
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 95
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 95
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 94
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 94
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 94
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 94
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 93
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 93
Combined therapy in pancreatic cancer 92
Phospholipase Cgamma1 is required for metastasis development and progression 92
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 92
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 92
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 92
Combinations of biological response modifiers: rationale and clinical responses. 92
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 92
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 92
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 91
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 91
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 91
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 90
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 90
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 90
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 89
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. 89
Prognostic value of gender and primary tumor location in metastatic colon cancer 89
Totale 11.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021676 0 0 0 0 0 229 36 15 59 194 82 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20253.627 200 751 610 90 64 97 124 189 320 186 402 594
2025/20263.292 553 358 707 796 572 306 0 0 0 0 0 0
Totale 18.300